GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Cryo-Cell International Inc (AMEX:CCEL) » Definitions » Forward PE Ratio

CCEL (Cryo-Cell International) Forward PE Ratio : 97.94 (As of Dec. 16, 2024)


View and export this data going back to . Start your Free Trial

What is Cryo-Cell International Forward PE Ratio?

Cryo-Cell International's Forward PE Ratio for today is 97.94.

Cryo-Cell International's PE Ratio without NRI for today is 41.90.

Cryo-Cell International's PE Ratio (TTM) for today is 0.00.


Cryo-Cell International Forward PE Ratio Historical Data

The historical data trend for Cryo-Cell International's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cryo-Cell International Forward PE Ratio Chart

Cryo-Cell International Annual Data
Trend 2024-12
Forward PE Ratio
97.94

Cryo-Cell International Quarterly Data
2024-12
Forward PE Ratio 97.94

Competitive Comparison of Cryo-Cell International's Forward PE Ratio

For the Medical Care Facilities subindustry, Cryo-Cell International's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cryo-Cell International's Forward PE Ratio Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Cryo-Cell International's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Cryo-Cell International's Forward PE Ratio falls into.



Cryo-Cell International Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Cryo-Cell International  (AMEX:CCEL) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Cryo-Cell International Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Cryo-Cell International's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Cryo-Cell International Business Description

Traded in Other Exchanges
Address
700 Brooker Creek Boulevard, Suite 1800, Oldsmar, FL, USA, 34677
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The Public cord blood banking segment consists of cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from cellular processing and cryogenic storage and it derives revenue from processing and testing fees and storage segment.
Executives
David Portnoy director, officer: Co-Chief Executive Officer C/O FOCUS FINANCIAL GROUP, 61 HARBOUR WAY, BAL HARBOUR FL 33154
George Gaines director 700 BROOKER CREEK BLVD, SUITE 1800, OLDSMAR FL 34677
Jonathan H. Wheeler director 700 BROOKER CREEK BLVD, SUITE 1800, OLDSMAR FL 34677
Brian L. Sheehy director 415 MADISON AVENUE, 14TH FLOOR, NEW YORK NY 10017
Mark L. Portnoy director, officer: Co-Chief Executive Officer 700 BROOKER CREEK BLVD, SUITE 1800, OLDSMAR FL 34677
Harold D. Berger director 700 BROOKER CREEK BLVD, SUITE 1800, OLDSMAR FL 34677
Arthur Ellis director 700 BROOKER CREEK BLVD, SUITE 1800, OLDSMAR FL 34677
Mary J Nyberg 10 percent owner 455 E MAYO BLVD, UNIT 5202, PHOENIX AZ 85050
Cdmj Nyberg Family Trust 10 percent owner 455 E MAYO BLVD, UNIT 5202, PHOENIX AZ 85050
Jill M Taymans officer: VP, Finance, CFO
Oleg Mikulinsky officer: Chief Information Officer 700 BROOKER CREEK BLVD., SUITE 1800, OLDSMAR FL 34677
Anthony Atala director 700 BROOKER CREEK BOULEVARD, OLDSMAR FL 34677
Scott G Christian director
Sung Won Sohn director 700 BROOKER CREEK BLVD., SUITE 1800, OLDSMAR FL 34677
Michael W. Cho director C/O IOWA STATE UNIVERSITY, 1600 S. 16TH STREET, AMES IA 50011-1250